FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

LC Swayne

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Living Beings

Mouse

Co-author Network

Publications

TOP 3
ME Juweid; George Hajjar; Rhona Stein; Robert M Sharkey; T Herskovic; LC Swayne; S Suleiman; M Pereira; AD Rubin; David M Goldenberg
Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
ME Juweid; Edward A Stadtmauer; George Hajjar; Robert M Sharkey; S Suleiman; Selina M Luger; LC Swayne; Abass Alavi; David M Goldenberg
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
ME Juweid; George Hajjar; LC Swayne; Robert M Sharkey; S Suleiman; T Herskovic; M Pereira; AD Rubin; David M Goldenberg
Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of LC Swayne (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2000: ME Juweid; George Hajjar; Rhona Stein; Robert M Sharkey; T Herskovic; LC Swayne; S Suleiman; M Pereira; AD Rubin; David M Goldenberg
Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(1):93-103.
1999: ME Juweid; Edward A Stadtmauer; George Hajjar; Robert M Sharkey; S Suleiman; Selina M Luger; LC Swayne; Abass Alavi; David M Goldenberg
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3292s-3303s.
1999: ME Juweid; George Hajjar; LC Swayne; Robert M Sharkey; S Suleiman; T Herskovic; M Pereira; AD Rubin; David M Goldenberg
Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
Cancer 1999;85(8):1828-42.
1998: ME Juweid; Robert M Sharkey; LC Swayne; Gary L Griffiths; R Dunn; David M Goldenberg
Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(1):34-42.
1997: ME Juweid; LC Swayne; Robert M Sharkey; R Dunn; AD Rubin; T Herskovic; David M Goldenberg
Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Gynecologic oncology 1997;67(3):259-71.
1997: ME Juweid; Robert M Sharkey; LC Swayne; David M Goldenberg
Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
Surgery 1997;122(6):1156-65.
1997: Thomas M Behr; Robert M Sharkey; ME Juweid; RM Dunn; R C Vagg; Zhiliang Ying; Chu-Hui Zhang; LC Swayne; Y Vardi; Jeffry A Siegel; David M Goldenberg
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(6):858-70.
1997: ME Juweid; Robert M Sharkey; Abass Alavi; LC Swayne; T Herskovic; D Hanley; AD Rubin; M Pereira; David M Goldenberg
Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(2):257-60.
1996: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; R Dunn; J Siegel; David M Goldenberg
Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(9):1504-10.
1996: ME Juweid; Robert M Sharkey; T M Behr; LC Swayne; R Dunn; Zhiliang Ying; Jeffry A Siegel; Hans J Hansen; David M Goldenberg
Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2.
Cancer 1996;78(1):157-68.
1996: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; T Herskovic; M Pereira; AD Rubin; D Hanley; R Dunn; J Siegel; David M Goldenberg
Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(6):905-11.
1996: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; AD Rubin; T Herskovic; D Hanley; A Markowitz; R Dunn; J Siegel; T Kamal; David M Goldenberg
Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1209-17.
1995: ME Juweid; Robert M Sharkey; T Behr; LC Swayne; AD Rubin; D Hanley; T Herskovic; A Markowitz; J Siegel; David M Goldenberg
Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
Cancer research 1995;55(23 Suppl):5946s-5951s.
1995: Robert M Sharkey; ME Juweid; J Shevitz; T Behr; R Dunn; LC Swayne; G Y Wong; Rosalyn D Blumenthal; Gary L Griffiths; Jeffry A Siegel
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
Cancer research 1995;55(23 Suppl):5935s-5945s.
1995: ME Juweid; Robert M Sharkey; A Markowitz; T Behr; LC Swayne; R Dunn; Hans J Hansen; J Shevitz; SO Leung; AD Rubin
Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Cancer research 1995;55(23 Suppl):5899s-5907s.
1994: David M Goldenberg; Robert M Sharkey; S Udem; R Vagg; G M Levine; P Conte; LC Swayne; H J Hansen; D Cunniff; J Anton
Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(6):1028-34.